GLP-1 Weight Loss Programs: Semaglutide & Tirzepatide
More than 40% of American adults are living with obesity [1]. If you are one of them, you already know that calorie counting and exercise programs have not worked the way they were supposed to. That is not a failure of effort. Research published by the National Institutes of Health shows that your body actively fights sustained weight loss through a process called metabolic adaptation, reducing the number of calories you burn and increasing hunger signals the longer you restrict food intake [2][3]. You are not losing a battle of willpower. You are fighting your own biology.
GLP-1 receptor agonists (specifically Semaglutide and Tirzepatide) are prescription medications that work by targeting the biological mechanisms behind appetite and weight regulation. In large-scale clinical trials published in the New England Journal of Medicine, these medications produced average weight reductions of 14.9% to 22.5% of body weight over 68 to 72 weeks [4][5]. They are not supplements, not diet pills, and not a shortcut. They are prescription therapies that a licensed provider evaluates, prescribes, and monitors as part of a broader treatment plan.
Transformation Health is an independent guide, not a provider: we do not prescribe or sell medication. Licensed providers at telehealth programs and clinics may prescribe brand-name versions of these medications or compounded versions prepared by licensed pharmacies. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
What’s in This Section
This section covers GLP-1 medications for weight loss from every angle – how they work, how to dose them, how to inject them safely, and answers to the most common questions. Use the sub-sections below to go deeper on any topic:
- How GLP-1 Medications Work – Mechanism of action, FDA-approved drugs, weight loss vs. diabetes use, and upcoming medications in development
- GLP-1 Dosing Reference – Dosing schedules, unit conversion tables, and side-by-side semaglutide vs. tirzepatide dose charts
- GLP-1 Injection Guide – Injection technique, best injection sites, how to prevent injection-site reactions, and injectable vs. oral comparison
- GLP-1 FAQ and Glossary – Common questions, eligibility, drug interactions, contraindications, and a full GLP-1 glossary
- GLP-1 and Weight Loss by State – Adult obesity rates and Medicaid GLP-1 coverage for all 50 states and DC, with telehealth access options
- GLP-1 Statistics – Verified usage, coverage, pricing, and clinical trial numbers, each traced to its primary source and dated
- Why Diets Stop Working – The biology of metabolic adaptation, why the weight comes back, and what actually changes the pattern after keto, calorie counting, and other diets stall
How GLP-1 Medications Work
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It plays a central role in how your brain regulates hunger, how quickly food moves through your stomach, and how your body manages blood sugar [6]. In people with obesity, these signaling pathways often do not function as they should. Think of it like a thermostat that has stopped reading the room temperature correctly: your brain keeps telling you to eat even when your body has plenty of stored energy.
GLP-1 medications amplify the natural effects of this hormone through three complementary mechanisms:
Appetite regulation
GLP-1 medications act on receptors in brain regions involved in appetite control, reducing hunger and what researchers describe as "food cue reactivity," the constant mental preoccupation with eating that people often call "food noise" [7]. Many people notice reduced food preoccupation within the first week or two of treatment.
Slowed gastric emptying
These medications slow how quickly food leaves your stomach, helping you feel full longer after meals [6]. You eat less because you genuinely feel satisfied, not because you are fighting cravings. This effect is one reason people report being comfortable with smaller portions without the constant sense of deprivation that comes with traditional calorie restriction.
Metabolic regulation
GLP-1 medications regulate insulin secretion and blood sugar levels, supporting metabolic health more broadly [6]. This is especially relevant for patients with insulin resistance, prediabetes, or type 2 diabetes. The SELECT trial (published in NEJM, 2023) also demonstrated a 20% reduction in major cardiovascular events in patients with obesity taking semaglutide [8].
Why this matters for women in perimenopause
If you are a woman between 35 and 55, the weight gain you have experienced over the past several years is likely not just about diet or activity level. Research shows that estrogen decline during the menopausal transition shifts where your body stores fat (from hips and thighs to the abdomen) and disrupts the appetite-regulating signals that GLP-1 medications target [9][10]. According to a review published in Climacteric, roughly 68% of women ages 40-59 are classified as overweight or obese, and the rate of weight gain accelerates during perimenopause regardless of changes in diet or exercise [11]. GLP-1 medications address both the appetite dysregulation and the metabolic shifts that make this stage of life so frustrating for weight management.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedSemaglutide vs. Tirzepatide: Understanding Your Options
Semaglutide and tirzepatide are the two active ingredients most often prescribed for weight management, and each has a distinct clinical profile. The provider you choose will recommend the option they determine is clinically appropriate based on your health profile, but understanding the differences helps you ask better questions and feel informed about your treatment plan.
Semaglutide is a GLP-1 receptor agonist. In the STEP 1 trial (1,961 participants, published in the New England Journal of Medicine), patients receiving semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. More than 86% of participants achieved at least 5% weight loss, and over 50% achieved 15% or more [4].
Tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it targets two hormonal pathways rather than one. In the SURMOUNT-1 trial (2,539 participants, also published in NEJM), participants receiving tirzepatide achieved average weight reductions of 15.0% (5 mg dose), 19.5% (10 mg dose), and 20.9% (15 mg dose) over 72 weeks [5]. The FDA approved tirzepatide for chronic weight management in November 2023 [12].
These results reflect the FDA-approved brand-name products studied under controlled trial conditions. Results vary. Trial results describe study participants and are not a prediction for any individual. Compounded semaglutide and tirzepatide contain the same molecules, but they are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness, or quality, and may differ in formulation, purity, and potency.
For a detailed side-by-side comparison of semaglutide, tirzepatide, and lower-dose approaches, see the GLP-1 medication comparison guide.
Who Is a Good Candidate for GLP-1 Treatment?
GLP-1 medications are not appropriate for everyone. At most telehealth programs, a licensed provider reviews your health history, current medications, and goals to decide whether treatment is clinically appropriate. Not sure where you stand? See what a provider typically evaluates before prescribing.
The American Medical Association recognized obesity as a chronic disease in 2013, and the National Institutes of Health identifies a BMI of 30 or higher as the clinical threshold for obesity [13]. According to the NIDDK, a provider may consider weight management medication for adults with a BMI of 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes. Brand-name semaglutide for weight management is also approved for adolescents ages 12 and older, while tirzepatide is approved for adults, and both are injected once a week [6]. The decision to prescribe is always made by the licensed provider you choose, based on your complete health picture.
What a proper weight loss program should include
Programs differ a lot in who provides your care and what happens after the first prescription. A treatment plan should be tailored to your health profile, not a one-size-fits-all protocol. Before you choose, check:
- Who the prescriber is (a physician, nurse practitioner, or physician assistant) and whether they are licensed in your state
- Whether lab work is required, and whether it is included or billed separately
- How follow-up works, including how you reach the provider and how dose adjustments are handled
- Whether the program offers nutrition guidance and exercise support, with emphasis on resistance training to preserve lean muscle mass [14]
- How side effects and questions are handled between visits
Also check what the monthly price includes (medication, dose increases, provider visits, labs, shipping, membership fees) and the cancellation terms. The GLP-1 cost guide explains how to compare the total cost.
What to Expect During GLP-1 Treatment
Understanding the timeline helps set realistic expectations. Individual experiences vary, and the provider you choose will track your progress and adjust your plan as needed. For a week-by-week guide, visit the patient guide.
Weeks 1-2: Getting started
GLP-1 medications start at a low dose and gradually increase (a process called titration). Many people notice mild appetite changes and reduced "food noise" within the first week [7]. Some experience mild nausea, which is the most commonly reported side effect in clinical trials and typically improves within a few days [4]. If side effects are hard to manage, contact the provider you choose about your dosing.
Weeks 2-8: Building habits
As your dose increases, appetite regulation becomes more pronounced. This is when healthy eating habits start to take hold because the biological barrier (constant hunger signaling) is reduced. A provider may recommend focusing on protein intake (research from the Endocrine Society suggests 1.2 to 1.6 grams per kilogram of body weight daily to help preserve lean muscle mass during weight loss [14][15]), adequate hydration, and gentle exercise.
Months 2-6: Continued progress
With continued treatment and lifestyle changes, many people see their most noticeable progress during this phase. In the STEP 1 trial, the majority of weight loss occurred in the first 6-8 months of treatment [4]. The provider you choose will typically monitor your response through follow-up visits and, when needed, lab work, and adjust your dose.
Months 6-12+: Long-term management
People who stay consistent with medication, nutrition, and exercise may continue to see improvements in weight and metabolic markers over time. Some providers discuss continuing at a lower maintenance dose, sometimes called microdosing. Dosing below the labeled maintenance dose is off-label, so ask about the evidence and the cost. The goal is to build habits that outlast the medication.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedThe Biology Behind Weight Regain (and Why Medication Helps)
If you have lost weight before and gained it back, it is worth understanding why. Research from the National Institutes of Health demonstrates that when you lose weight through calorie restriction alone, your body lowers its resting metabolic rate by more than what would be expected from the weight loss itself [2]. A landmark NIH study of Biggest Loser contestants found that this metabolic adaptation persisted for at least six years after the competition, with participants burning an average of 499 fewer calories per day than expected for their body size [3].
At the same time, levels of leptin (the hormone that signals fullness) drop, while ghrelin (the hormone that signals hunger) increases [2]. Your body is essentially working against you, demanding more food while burning less energy. This is not a failure of discipline. It is a well-documented survival mechanism.
GLP-1 medications address this cycle directly. By reducing appetite signaling at the brain level and slowing gastric emptying, they create the conditions for sustained calorie reduction without the compensatory hunger surge that derails most diet-only approaches [6][7]. Combined with nutrition guidance, exercise, and medical monitoring, this is what a medically supervised weight loss program looks like.
The Getting-Started Process
At most telehealth programs, getting a GLP-1 prescription happens online, with no office visit or waiting room. The steps, timing, and costs vary by program, so check each program’s process before you sign up. For more detail, see how getting a GLP-1 prescription online works.
1. Compare providers
Look at who prescribes, which medications they offer, what the price includes, and the cancellation terms before you choose a program.
2. Provider evaluation
At the program you choose, a licensed provider reviews your health history and current medications and decides whether a prescription is clinically appropriate.
3. Prescription filled
If a provider prescribes, a licensed pharmacy fills the prescription. Shipping costs and delivery times vary by program and pharmacy.
Some states have additional telehealth rules, such as a live video visit before a first prescription. The provider you choose will explain what applies where you live. Learn more in the guide to getting a prescription online.
Pricing and What’s Included
Many self-pay telehealth programs advertise a single monthly price, but what that price covers varies. Some bundle medication, provider visits, lab work, and shipping; others charge for some of these separately or change the price as your dose increases. Prices vary by program, medication, and dose. For current market prices with sources and capture dates, see the GLP-1 cost guide.
| What to check | Questions to ask | Why it matters |
|---|---|---|
| Medication | Brand-name or compounded? Which dose is the price for? | Prices can change as the dose increases |
| Provider visits | Are the first visit and follow-ups included? | Some programs bill visits separately |
| Lab work | Are labs required, and who pays for them? | Some programs include labs; others bill separately |
| Shipping and fees | Are there shipping, membership, or setup fees? | These add to the monthly total |
| Cancellation terms | How do you cancel, and are you billed in advance? | Terms differ by program |
Brand-name and compounded GLP-1 medications are priced differently, and what you pay for a brand-name product depends on your insurance coverage and manufacturer programs. Compounded medications are different products from brand-name drugs. They are prepared by licensed pharmacies and are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. Read the full cost and pricing breakdown for a detailed comparison.
Transformation Health does not accept payment from providers. How we make money.
Citations
- CDC National Center for Health Statistics. “Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.” NCHS Data Brief No. 508, September 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
- Muller MJ, Bosy-Westphal A. “Adaptive thermogenesis with weight loss in humans.” Obesity. 2013;21(2):218-228. https://pmc.ncbi.nlm.nih.gov/articles/PMC3673773/
- Fothergill E, et al. “Persistent metabolic adaptation 6 years after The Biggest Loser competition.” Obesity. 2016;24(8):1612-1619. https://pmc.ncbi.nlm.nih.gov/articles/PMC4989512/
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight and Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
- Dalton B, et al. “What Is Food Noise? A Conceptual Model of Food Cue Reactivity.” Nutrients. 2023;15(22):4809. https://pmc.ncbi.nlm.nih.gov/articles/PMC10674813/
- Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Greendale GA, et al. “Changes in body composition and weight during the menopause transition.” JCI Insight. 2019;4(5):e124865. https://pmc.ncbi.nlm.nih.gov/articles/PMC6483504/
- Kapoor E, et al. “Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management.” Mayo Clinic Proceedings. 2017;92(10):1552-1558. https://pmc.ncbi.nlm.nih.gov/articles/PMC8373626/
- Davis SR, et al. “Understanding weight gain at menopause.” Climacteric. 2012;15(5):419-429. https://pubmed.ncbi.nlm.nih.gov/22978257/
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information (NDA 217806). Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf. Original approval date (11/08/2023) from Drugs@FDA: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Treatment for Overweight and Obesity.” https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment
- Endocrine Society. “Consuming more protein may protect patients taking anti-obesity drug from muscle loss.” ENDO 2025 Press Release. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/haines-press-release
- Neeland IJ, et al. “Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.” Diabetes, Obesity and Metabolism. 2024;26(5):1732-1750. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728